
Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into Phase 1 Psoriasis Trial
Ascletis Pharma, Inc. announced today that the US FDA has cleared its investigational new drug application for a phase 1 trial of its oral small molecule inhibitor targeting IL-17.1 The drug, ASC50, will be assessed in patients with mild to moderate plaque …